AML blasts were specifically targeted by SAR T cells in the presence of the anti-E3–anti-CD33 molecule, whereas control T cell and taFv combinations were not (Fig. 4A, B and Supplementary Fig. 3B, C). The gene discussed is CD33; the disease is acute myeloid leukemia.